Simple Production of Yttrium-90 in a Chemical form Suitable to Clinical Grade Radioconjugates

Chinol, Marco; Franceschini, R; Paganelli, Giovanni; Pecorale, A; Paiano, A.

doi:10.1007/978-3-0348-7772-5_49

Cited by 8 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of solvent extraction and ion exchange methods have been reported for the separation of 90 Y from 90 Sr [15][16][17][18]. In most of those generators, 90 Y is eluted as a complex which is then destroyed to obtain 90 Y(III) for preparation of the complex of interest.…”

mentioning

confidence: 99%

Complexation studies with ⁹⁰Y from a novel ⁹⁰Sr-⁹⁰Y generator

Venkatesh¹,

Pandey²,

Dhami³

et al. 2001

Radiochimica Acta

View full text Add to dashboard Cite

90 Sr-90 Y generator / Supported liquid membrane / 90 Sr breakthrough / 90 Y purity / 90 Y radiopharmaceuticals Summary. Some features of a novel 90 Sr-90 Y generator which employs supported liquid membrane (SLM) to separate carrier-free 90 Y from 90 Sr present in the high level waste of the spent fuel of reactor are described. After ascertaining the purity of 90 Y particularly with respect to 90 Sr breakthrough, its complexation was studied with a few oxo/aza donor ligands, such as DTPA, EDTMP, DOTA, TETA and a cyclic phosphonate, CTMP. These studies were primarily carried out to adjudge the quality of the 90 Y obtained from a novel 90 Sr-90 Y generator and ascertain its usability for labelling biomolecules such as antibodies and peptides. The DOTA complexes are most stable at 37 • C in human serum; they appear to be ideal bifunctional chelating agent for use in radioimmunotherapy with 90 Y.

show abstract

mentioning

confidence: 99%

Complexation studies with ⁹⁰Y from a novel ⁹⁰Sr-⁹⁰Y generator

Venkatesh¹,

Pandey²,

Dhami³

et al. 2001

Radiochimica Acta

View full text Add to dashboard Cite

show abstract

“…Out of these, 90 Y and 177 Lu are the two favorable isotopes due to their higher particle energies compared to 111 In. 90 Y (t 1/2 = 64.2 h) emits β − -particles with a maximum energy of 2.284 MeV, allowing penetration of soft tissue to a depth of around 11 mm (50,51). Because of its longer range compared to 177 Lu, 90 Y-DOTATE/TOC is suggested to be more suitable for bigger lesions, while 177 Lu-DOTATATE might be preferred for smaller lesions (52).…”

Section: Choosing a Radionuclide For Peptide Receptor Radionuclide Th...mentioning

confidence: 99%

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

et al. 2022

View full text Add to dashboard Cite

Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding clinical applications. By chelating a radiometal to a somatostatin receptor (SSTR) ligand, radiation can be delivered to cancer cells with high precision. Unlike conventional external beam radiotherapy, PRRT utilizes primarily β or α radiation derived from nuclear decay, which causes damage to cancer cells in the immediate proximity by irreversible direct or indirect ionization of the cells’ DNA, which induces apoptosis. In addition, to avoid damage to surrounding normal cells, PRRT privileges the use of radionuclides that have little penetrating and more energetic (and thus more ionizing) radiations. To date, the most frequently radioisotopes are β– emitters, particularly Yttrium-90 (90Y) and Lutetium-177 (177Lu), labeled SSTR agonists. Current development of SSTR-targeting is triggering the shift from using SSTR agonists to antagonists for PRRT. Furthermore, targeted α-particle therapy (TAT), has attracted special attention for the treatment of tumors and offers an improved therapeutic option for patients resistant to conventional treatments or even beta-irradiation treatment. Due to its short range and high linear energy transfer (LET), α-particles significantly damage the targeted cancer cells while causing minimal cytotoxicity toward surrounding normal tissue. Actinium-225 (225Ac) has been developed into potent targeting drug constructs including somatostatin-receptor-based radiopharmaceuticals and is in early clinical use against multiple neuroendocrine tumor types. In this article, we give a review of preclinical and clinical applications of 225Ac-PRRT in NETs, discuss the strengths and challenges of 225Ac complexes being used in PRRT; and envision the prospect of 225Ac-PRRT as a future alternative in the treatment of NETs.

show abstract

“…Researchers have shown that yttrium-90 coupled to DOTA-TATE also elicits a significant clinical and radiological response in NET patients [ 27 ]. Yttrium-90 has a half-life of 64.2 hours and emits β - -particles with a maximum energy of 2.27 MeV, which can penetrate soft tissue to a depth of around 11 mm [ 28 , 29 ]. Its particles have a longer range compared to lutetium-177, and therefore it has been hypothesized that PRRT using [ 90 Y]Y-[DOTA-Tyr 3 ]octreotide (DOTA-TOC) or [ 90 Y]Y-DOTA-TATE is more suited for bigger lesions, while [ 177 Lu]Lu-DOTA-TATE treatment is preferred for smaller lesions [ 30 ].…”

Section: Improving Peptide Receptor Radionuclide Therapymentioning

confidence: 99%

Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward

Feijtel

Jong

Nonnekens

2020

CTMC

View full text Add to dashboard Cite

Peptide receptor radionuclide therapy (PRRT) is a highly effective anti-cancer treatment modality for patients with non-resectable, metastasized neuroendocrine tumors (NETs). During PRRT, specific receptors that are overexpressed on the cancer cells are targeted with a peptide labeled with a DNA-damaging radionuclide. Even though PRRT is a powerful treatment for metastasized NET patients, the majority still cannot be cured at this stage of the disease. Hence, many investigators focus on improving the therapeutic efficacy of this therapy. Improving PRRT can for example be achieved by using other radionuclides with different physical properties, by combining PRRT with radiosensitizing agents or by radiolabeling peptides with different characteristics. However, due to lack of extensive knowledge of radiobiological responses of cancer cells to PRRT, biological parameters that influence absorbed dose or that might even elicit insensitivity to therapy remain elusive and the context in which these improvements will be successful warrants further investigation. In this review we will discuss the development of PRRT, its clinical merits in current treatment and the future perspectives. We will highlight different radionuclides and their benefits and pitfalls, as well as different peptide-conjugates that hold these radionuclides. We will zoom in on the latest developments regarding combinatorial treatments and how investigators from different disciplines such as dosimetry and radiobiology are now joining forces to improve PRRT for NETs.

show abstract

Simple Production of Yttrium-90 in a Chemical form Suitable to Clinical Grade Radioconjugates

Cited by 8 publications

References 2 publications

Complexation studies with ⁹⁰Y from a novel ⁹⁰Sr-⁹⁰Y generator

Complexation studies with ⁹⁰Y from a novel ⁹⁰Sr-⁹⁰Y generator

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward

Contact Info

Product

Resources

About

Simple Production of Yttrium-90 in a Chemical form Suitable to Clinical Grade Radioconjugates

Cited by 8 publications

References 2 publications

Complexation studies with 90Y from a novel 90Sr-90Y generator

Complexation studies with 90Y from a novel 90Sr-90Y generator

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward

Contact Info

Product

Resources

About

Complexation studies with ⁹⁰Y from a novel ⁹⁰Sr-⁹⁰Y generator

Complexation studies with ⁹⁰Y from a novel ⁹⁰Sr-⁹⁰Y generator